Teva Edges Closer To Growth, But With A Big Overhang
Teva's turnaround is progressing, but the company forecast largely flat revenues and earnings in 2020. A threat to the improved stability is how an opioid litigation settlement might unfold.
You may also be interested in...
Israeli giant Teva is hoping to follow the recent big-ticket launches of generic Truvada/Atripla and NuvaRing with multiple complex generics launches in the US this year. Management discussed individual product opportunities as Teva disclosed full-year financial earnings.
The company's specialty franchises are on track for solid growth but the North American generics outlook remains lackluster.
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles.